ClinicalTrials.gg
CompletedNCT02720627Updated Nov 20, 2020Results posted

An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris

A Phase 2 interventional study of cortexolone 17α-propionate in Acne Vulgaris, sponsored by Cassiopea SpA. Completed at 10 sites in 2 countries. Open to participants aged 9 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-11-20.

Sponsored by Cassiopea SpA · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
9 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Enrollment
13th of 19
27 · median 50
Started
2016
with 2 others
Phase 2
3 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
4 of 19
Cassiopea SpA

Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 13th largest by enrollment, is one of 3 that started in 2016, is one of 3 in phase 2, and was the 6th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9 to less than 12 years of age with acne vulgaris. Adrenal suppression effects and systemic safety are an important safety concern. The current study is designed to investigate these potential concerns under maximal use conditions.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • acne
  • cortexolone
  • anti-androgen
04

Who can participate

Ages eligible
9 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian must provide written for the patient.
  • Patient has moderate to severe facial acne vulgaris as determined by the Investigator and obvious acne on the trunk (i.e., shoulders, upper chest, and/or back).
  • Females of must be using highly effective methods with a negative urine pregnancy test (UPT) at study start.
  • Patient must be in general good health with normal renal function and no abnormalities present at study start.
  • Patient and parent/guardian are able to communicate with the staff and are willing to comply with study instructions, reside at and/or return to the clinic for required visits.

Exclusion criteria

Exclusion Criteria:

  • Patient is pregnant, lactating, or is planning to become pregnant during the study.
  • Patient has a (BMI) for age percentile > 95%.
  • Patient has any skin or medical condition, including facial hair that could interfere with the evaluation of the test article or requires the use of interfering topical or systemic therapy.
  • Patient has received an drug or been treated with an investigational device within 30 days prior to study start.
  • Patient is currently enrolled in an investigational drug or device study.
  • Patient has any condition which, in the investigator's opinion, would make it unsafe for the patient to participate in this research study.
  • Patient has known allergy or sensitivity to CB-03-01 or any of its ingredients
  • Patient has participated in a previous CB-03-01 study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    CB-03-01 cream, 1%

    Topical CB-03-01 (cortexolone 17α-propionate) cream containing 1% active drug applied to the face and trunk twice daily for 14 days

    Drug: cortexolone 17α-propionate

Interventions

  • CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.

    Also known as: CB-03-01

06

What researchers measure

Primary outcomes

  1. Change in HPA Axis Response as Measured by CST

    Measurement of serum cortisol concentrations after stimulation of the adrenal cortex with cosyntropin (Cosyntropin Stimulation Test - CST). HPA axis suppression is defined as a post-stimulation serum cortisol level ≤ 18 μg/dL at Day 14.

    Time frame: Pre- and Post-CST on Day 14

Secondary outcomes

  1. Evaluate Trough Plasma Concentrations

    Trough (single blood draw approximately 12 hours post the most recent dose) measurements of cortexolone 17α-propionate (clascoterone) concentration in plasma at Screening, Baseline, Day 7 and Day 14.

    Time frame: 14 Days

07

Results

Posted Oct 19, 2020

Participant flow

Participant flow — Overall Study
MilestoneCB-03-01 Cream, 1%
Started27
Completed27
Not completed0

Outcome measures

PrimaryChange in HPA Axis Response as Measured by CST

Measurement of serum cortisol concentrations after stimulation of the adrenal cortex with cosyntropin (Cosyntropin Stimulation Test - CST). HPA axis suppression is defined as a post-stimulation serum cortisol level ≤ 18 μg/dL at Day 14.

Time frame:
Pre- and Post-CST on Day 14
Reported as:
Mean · mcg/dL
Change in HPA Axis Response as Measured by CST
mcg/dLCB-03-01 Cream, 1%
Cortisol level (Pre-CST)12.50 ± 4.90
Cortisol level (Post-CST)22.95 ± 3.20
SecondaryEvaluate Trough Plasma Concentrations

Trough (single blood draw approximately 12 hours post the most recent dose) measurements of cortexolone 17α-propionate (clascoterone) concentration in plasma at Screening, Baseline, Day 7 and Day 14.

Time frame:
14 Days
Reported as:
Mean · ng/mL
Evaluate Trough Plasma Concentrations
ng/mLCB-03-01 Cream, 1%
Screening0.0 ± 0.0
Baseline (Day 1)0.027 ± 0.136
Day 70.577 ± 1.01
Day 140.606 ± 0.701

Adverse events

Collected over 14 Days or up to 42 days for those with laboratory evidence of adrenal suppression (i.e., post-stimulation serum cortisol level ≤18 μg/dL at Day 14).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CB-03-01 Cream, 1%0/27 (0%)0/27 (0%)5/27 (18.5%)
Most frequent other events
Most frequent other events
EventCB-03-01 Cream, 1%
ACTH stimulation test abnormalInvestigations4/27
LeukopeniaBlood and lymphatic system disorders1/27

Baseline characteristics

Safety Population, defined as all enrolled subjects who were dispensed and applied at least one dose of the test article. All enrolled subjects were included in the safety population.

Age, Continuous
Age, Continuous(years)CB-03-01 Cream, 1%
Mean10.2 ± 0.9
Sex: Female, Male
Sex: Female, Male(Participants)CB-03-01 Cream, 1%
Female22
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CB-03-01 Cream, 1%
Hispanic or Latino7
Not Hispanic or Latino20
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CB-03-01 Cream, 1%
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White25
More than one race0
Unknown or Not Reported0
Baseline HPA Axis Response
Baseline HPA Axis Response(mcg/dL)CB-03-01 Cream, 1%
Cortisol Level (Pre-CST)13.53 ± 4.53
Cortisol Level (Post-CST)24.87 ± 3.70
08

Study locations

10 sites
  • Site 103
    Fort Smith, Arkansas 72916, United States
  • Site 101
    San Diego, California 92037, United States
  • Site 102
    Houston, Texas 77030, United States
  • Site 4814
    Czestochowa, Poland
  • Site 4811
    Katowice, Poland
  • Site 4813
    Kraków, Poland
  • Site 4815
    Kraków, Poland
  • Site 4816
    Rzeszów, Poland
  • Site 4812
    Szczecin, Poland
  • Site 4817
    Tarnów, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Mar 2018, 16 months.

Results were first posted in Oct 2020, 2 years 6 months after primary completion. A results delay was requested in Jun 2019.

Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 16 months is above that.

Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2016
First posted
Mar 28, 2016
StartActual
Oct 28, 2016
Primary completionActual
Mar 21, 2018
CompletionActual
Mar 21, 2018
Results delay requested
Jun 7, 2019
Results first posted
Oct 19, 2020
Last update
Nov 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02720627
Lead sponsor
Cassiopea SpA
Responsible party
Sponsor
First posted
Mar 28, 2016
Start date
Oct 28, 2016
Primary completion
Mar 21, 2018
Completion
Mar 21, 2018
Results posted
Oct 19, 2020
Last update
Nov 20, 2020

Study contacts

R&D Department
study director · Cassiopea SpA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion